Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 5/2015

01-06-2015

Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation

Authors: Carmela Ricciardelli, Noor A. Lokman, Sowmya Cheruvu, Izza A. Tan, Miranda P. Ween, Carmen E. Pyragius, Andrew Ruszkiewicz, Peter Hoffmann, Martin K. Oehler

Published in: Clinical & Experimental Metastasis | Issue 5/2015

Login to get access

Abstract

Ovarian cancer, the most lethal gynaecological cancer, is characterised by the shedding of epithelial cells from the ovarian surface, followed by metastasis and implantation onto the peritoneal surfaces of abdominal organs. Our proteomic studies investigating the interactions between peritoneal (LP-9) and ovarian cancer (OVCAR-5) cells found transketolase (TKT) to be regulated in the co-culture system. This study characterized TKT expression in advanced stage (III/IV) serous ovarian cancers (n = 125 primary and n = 54 peritoneal metastases), normal ovaries (n = 6) and benign serous cystadenomas (n = 10) by immunohistochemistry. In addition, we also evaluated the function of TKT in ovarian cancer cells in vitro. Nuclear TKT was present in all primary serous ovarian cancer tissues examined (median 82.0 %, range 16.5–100 %) and was significantly increased in peritoneal metastases compared with matching primary cancers (P = 0.01, Wilcoxon Rank test). Kaplan–Meier survival and Cox regression analyses showed that high nuclear TKT positivity in peritoneal metastases (>94 %) was significantly associated with reduced overall survival (P = 0.006) and a 2.8 fold increased risk of ovarian cancer death (95 % CI 1.29–5.90, P = 0.009). Knockdown of TKT by siRNAs significantly reduced SKOV-3 cell proliferation but had no effect on their motility or invasion. Oxythiamine, an inhibitor of TKT activity, significantly inhibited the proliferation of four ovarian cancer cell lines (OV-90, SKOV-3, OVCAR-3 and OVCAR-5) and primary serous ovarian cancer cells isolated from patient ascites. In conclusion, these findings indicate that TKT plays an important role in the proliferation of metastatic ovarian cancer cells and could be used as novel therapeutic target for advanced disease.
Appendix
Available only for authorised users
Literature
1.
2.
Auersperg N et al (2001) Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22(2):255–288PubMed
3.
Gardner MJ et al (1995) Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. Cancer Lett 91(2):229–234PubMedCrossRef
4.
5.
Strobel T, Cannistra SA (1999) Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol 73(3):362–367PubMedCrossRef
6.
Ricciardelli C, Rodgers RJ (2006) Extracellular matrix of ovarian tumors. Semin Reprod Med 24(4):270–282PubMedCrossRef
7.
8.
Heyman L et al (2008) Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro. Tumour Biol 29(4):231–244PubMedCrossRef
9.
Kenny HA et al (2008) The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Investig 118(4):1367–1379PubMedCentralPubMedCrossRef
10.
Ween MP et al (2011) Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. Int J Cancer 128(7):1570–1584PubMedCrossRef
11.
Lokman NA et al (2013) Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis. Oncotarget 4(8):1199–1211PubMedCentralPubMed
12.
Lindqvist Y et al (1992) Three-dimensional structure of transketolase, a thiamine diphosphate dependent enzyme, at 2.5 A resolution. EMBO J 11(7):2373–2379PubMedCentralPubMed
13.
Zhao J, Zhong CJ (2009) A review on research progress of transketolase. Neurosci Bull 25(2):94–99PubMedCrossRef
14.
Cascante M et al (2000) Role of thiamin (vitamin B-1) and transketolase in tumor cell proliferation. Nutr Cancer 36(2):150–154PubMedCrossRef
15.
Blass JP, Gibson GE (1977) Abnormality of a thiamine-requiring enzyme in patients with Wernicke–Korsakoff syndrome. N Engl J Med 297(25):1367–1370PubMedCrossRef
16.
Gibson GE et al (1988) Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer’s disease. Arch Neurol 45(8):836–840PubMedCrossRef
17.
Boros LG et al (1997) Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res 57(19):4242–4248PubMed
18.
Boros LG et al (2000) Transforming growth factor beta2 promotes glucose carbon incorporation into nucleic acid ribose through the nonoxidative pentose cycle in lung epithelial carcinoma cells. Cancer Res 60(5):1183–1185PubMed
19.
Boros LG et al (1998) Inhibition of the oxidative and nonoxidative pentose phosphate pathways by somatostatin: a possible mechanism of antitumor action. Med Hypotheses 50(6):501–506PubMedCrossRef
20.
Rais B et al (1999) Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich’s tumor cells through inhibition of the pentose cycle. FEBS Lett 456(1):113–118PubMedCrossRef
21.
Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4(11):891–899PubMedCrossRef
22.
Seyfried TN, Shelton LM (2010) Cancer as a metabolic disease. Nutr Metab 7:7CrossRef
23.
24.
Kelloff GJ et al (2005) Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11(8):2785–2808PubMedCrossRef
25.
Kelloff GJ et al (2007) FDG-PET lymphoma demonstration project invitational workshop. Acad Radiol 14(3):330–339PubMedCrossRef
26.
Lavayssiere R, Cabee AE, Filmont JE (2009) Positron emission tomography (PET) and breast cancer in clinical practice. Eur J Radiol 69(1):50–58PubMedCrossRef
27.
Wittig R, Coy JF (2008) The role of glucose metabolism and glucose-associated signalling in cancer. Perspect Med Chem 1:64–82
28.
Boren J et al (2002) Metabolic control analysis aimed at the ribose synthesis pathways of tumor cells: a new strategy for antitumor drug development. Mol Biol Rep 29(1–2):7–12PubMedCrossRef
29.
Ramos-Montoya A et al (2006) Pentose phosphate cycle oxidative and nonoxidative balance: a new vulnerable target for overcoming drug resistance in cancer. Int J Cancer 119(12):2733–2741PubMedCrossRef
30.
Langbein S et al (2006) Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: warburg effect reinterpreted. Br J Cancer 94(4):578–585PubMedCentralPubMedCrossRef
31.
Coy JF et al (1996) Molecular cloning of tissue-specific transcripts of a transketolase-related gene: implications for the evolution of new vertebrate genes. Genomics 32(3):309–316PubMedCrossRef
32.
33.
Coy JF et al (2005) Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. Clin Lab 51(5–6):257–273PubMed
34.
Kochetov GA, Solovjeva ON (2014) Structure and functioning mechanism of transketolase. Biochim Biophys Acta 9(1844):1608–1618CrossRef
35.
Staiger WI et al (2006) Expression of the mutated transketolase TKTL1, a molecular marker in gastric cancer. Oncol Rep 16(4):657–661PubMed
36.
Foldi M et al (2007) Transketolase protein TKTL1 overexpression: a potential biomarker and therapeutic target in breast cancer. Oncol Rep 17(4):841–845PubMed
37.
Zhang S et al (2007) Gene silencing of TKTL1 by RNAi inhibits cell proliferation in human hepatoma cells. Cancer Lett 253(1):108–114PubMedCrossRef
38.
Volker HU et al (2007) Overexpression of transketolase TKTL1 is associated with shorter survival in laryngeal squamous cell carcinomas. Eur Arch Oto-Rhino-Laryngol 264(12):1431–1436CrossRef
39.
Volker HU et al (2008) Expression of transketolase-like 1 and activation of Akt in grade IV glioblastomas compared with grades II and III astrocytic gliomas. Am J Clin Pathol 130(1):50–57PubMedCrossRef
40.
Langbein S et al (2008) Metastasis is promoted by a bioenergetic switch: new targets for progressive renal cell cancer. Int J Cancer 122(11):2422–2428PubMedCrossRef
41.
Zhang S et al (2008) Overexpression of transketolase protein TKTL1 is associated with occurrence and progression in nasopharyngeal carcinoma: a potential therapeutic target in nasopharyngeal carcinoma. Cancer Biol Ther 7(4):517–522PubMedCrossRef
42.
Chen H et al (2009) Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer. J Exp Clin Cancer Res 28:43PubMedCentralPubMedCrossRef
43.
Kayser G et al (2011) Poor outcome in primary non-small cell lung cancers is predicted by transketolase TKTL1 expression. Pathology 43(7):719–724PubMedCrossRef
44.
Grimm M et al (2013) A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells. BMC Cancer 13:569PubMedCentralPubMedCrossRef
45.
Grimm M et al (2014) GLUT-1(+)/TKTL1(+) coexpression predicts poor outcome in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol 117(6):743–753PubMedCrossRef
46.
Krockenberger M et al (2007) Transketolase-like 1 expression correlates with subtypes of ovarian cancer and the presence of distant metastases. Int J Gynecol Cancer 17(1):101–106PubMedCrossRef
47.
Mayer A, Von Wallbrunn A, Vaupel P (2010) Glucose metabolism of malignant cells is not regulated by transketolase-like (TKTL)-1. Int J Oncol 37(2):265–271PubMedCrossRef
48.
Mayer A, Von Wallbrunn A, Vaupel P (2011) Evidence against a major role for TKTL-1 in hypoxic and normoxic cancer cells. Adv Exp Med Biol 701:123–128PubMed
49.
Bentz S et al (2013) Hypoxia induces the expression of transketolase-like 1 in human colorectal cancer. Digestion 88(3):182–192PubMedCrossRef
50.
Wanka C, Steinbach JP, Rieger J (2012) Tp53-induced glycolysis and apoptosis regulator (TIGAR) protects glioma cells from starvation-induced cell death by up-regulating respiration and improving cellular redox homeostasis. J Biol Chem 287(40):33436–33446PubMedCentralPubMedCrossRef
51.
Sun W et al (2010) TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization. Clin Cancer Res 16(3):857–866PubMedCentralPubMedCrossRef
52.
Maslova AO, Meshalkina LE, Kochetov GA (2012) Computer modeling of transketolase-like protein, TKTL1, a marker of certain tumor tissues. Biochem Biokhimiia 77(3):296–299CrossRef
53.
Meshalkina LE et al (2013) Is transketolase-like protein, TKTL1, transketolase? Biochim Biophys Acta 1832(3):387–390PubMedCrossRef
54.
Schneider S et al (2012) A delta38 deletion variant of human transketolase as a model of transketolase-like protein 1 exhibits no enzymatic activity. PLoS ONE 7(10):e48321PubMedCentralPubMedCrossRef
55.
Yuan W et al (2010) Silencing of TKTL1 by siRNA inhibits proliferation of human gastric cancer cells in vitro and in vivo. Cancer Biol Ther 9(9):710–716PubMedCrossRef
56.
Xu X et al (2009) Transketolase-like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells. Int J Cancer 124(6):1330–1337PubMedCrossRef
57.
Zhao F et al (2010) Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene 29(20):2962–2972PubMedCentralPubMedCrossRef
58.
Liu H et al (2010) Fructose induces transketolase flux to promote pancreatic cancer growth. Cancer Res 70(15):6368–6376PubMedCrossRef
59.
Shimizu T et al (2014) Frequent alteration of the protein synthesis of enzymes for glucose metabolism in hepatocellular carcinomas. J Gastroenterol 49(9):1324–1332PubMedCentralPubMedCrossRef
60.
61.
Lin CC et al (2011) Malignant pleural effusion cells show aberrant glucose metabolism gene expression. Eur Respir J 37(6):1453–1465PubMedCrossRef
62.
Mohd Omar MF et al (2010) Molecular-assisted immunohistochemical optimization. Acta Histochem 112(6):519–528PubMedCrossRef
63.
Uhlen M et al (2010) Towards a knowledge-based human protein atlas. Nat Biotechnol 28(12):1248–1250PubMedCrossRef
64.
65.
Paoletti F, Mocali A, Tombaccini D (1997) Cysteine proteinases are responsible for characteristic transketolase alterations in Alzheimer fibroblasts. J Cell Physiol 172(1):63–68PubMedCrossRef
66.
Vizan P et al (2009) Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29. Int J Cancer 124(12):2789–2796PubMedCrossRef
67.
68.
Basu TK, Dickerson JW (1976) The thiamin status of early cancer patients with particular reference to those with breast and bronchial carcinomas. Oncology 33(5–6):250–252PubMedCrossRef
69.
Comin-Anduix B et al (2001) The effect of thiamine supplementation on tumour proliferation. A metabolic control analysis study. Eur J Biochem FEBS 268(15):4177–4182CrossRef
70.
Pamukcu AM et al (1970) Effects of the coadministration of thiamine on the incidence of urinary bladder carcinomas in rats fed bracken fern. Cancer Res 30(11):2671–2674PubMed
71.
Lu’o’ng KV, Nguyen LT (2013) The role of thiamine in cancer: possible genetic and cellular signaling mechanisms. Cancer Genomics Proteomics 10(4):169–185PubMed
72.
Zhang H et al (2010) Inhibition of protein phosphorylation in MIA pancreatic cancer cells: confluence of metabolic and signaling pathways. J Proteome Res 9(2):980–989PubMedCentralPubMedCrossRef
73.
Yang CM et al (2010) The in vitro and in vivo anti-metastatic efficacy of oxythiamine and the possible mechanisms of action. Clin Exp Metastasis 27(5):341–349PubMedCrossRef
74.
Ji H et al (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448(7155):807–810PubMedCrossRef
75.
Metadata
Title
Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation
Authors
Carmela Ricciardelli
Noor A. Lokman
Sowmya Cheruvu
Izza A. Tan
Miranda P. Ween
Carmen E. Pyragius
Andrew Ruszkiewicz
Peter Hoffmann
Martin K. Oehler
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 5/2015
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-015-9718-1

Other articles of this Issue 5/2015

Clinical & Experimental Metastasis 5/2015 Go to the issue

Research Paper

Nidogen 1 and Nuclear Protein 1: novel targets of ETV5 transcription factor involved in endometrial cancer invasion

Research Paper

Loss of PCDH9 is associated with the differentiation of tumor cells and metastasis and predicts poor survival in gastric cancer

Research Paper

Hepatoprotective and anti-tumor effects of targeting MMP-9 in hepatocellular carcinoma and its relation to vascular invasion markers

Research Paper

Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases

Research Paper

Activation of tumour cell ECM degradation by thrombin-activated platelet membranes: potentially a P-selectin and GPIIb/IIIa-dependent process

Research Paper

Amino-terminal fragments of laminin γ2 chain stimulate migration of metastatic breast cancer cells by interacting with CD44
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits